{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-086860","form_type":"8-K","ticker":"QNRX","cik":"0001671502","company_name":"Quoin Pharmaceuticals, Ltd.","filed_at":"2023-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.797235+00:00","generated_at":"2026-06-12T13:55:15.646358+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Quoin posts Q2 net loss $2.1M, reports positive clinical data for first Netherton Syndrome subject","bullets":["Cash, equivalents and securities at June 30, 2023: ~$15.4M; runway extends into 2H 2024.","Net loss Q2 2023: ~$2.1M vs ~$2.7M in Q2 2022; first-half 2023 loss ~$4.7M.","First subject in open-label Netherton Syndrome study showed fully clear skin at QRX003 treatment sites and substantial pruritis improvement.","Majority of patients across both Netherton Syndrome studies expected to be enrolled by end of August 2023.","Regained Nasdaq minimum bid price compliance; closing bid price at $1.00+ for 10 consecutive days."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-086860","json":"https://secwatch.observer/filing/0001104659-23-086860.json","markdown":"https://secwatch.observer/filing/0001104659-23-086860.md","text":"https://secwatch.observer/filing/0001104659-23-086860.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671502/000110465923086860/0001104659-23-086860-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671502/000110465923086860/tm2322693d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T13:55:15.646358+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"33963f7f44cd25fdcc38b554c913cfc105af391b","claim":"Quoin Pharmaceuticals, Ltd. reported quarter ended June 30, 2023 results: net income Net loss for the quarter ended June 30, 2023 was approximately $2.1 million compared to approximately $2.7 million for t.","evidence_excerpt":"On August 2, 2023, Quoin Pharmaceuticals Ltd. (the “Company”) announced its financial results for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671502/000110465923086860/0001104659-23-086860-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended June 30, 2023"},{"label":"Net income","value":"Net loss for the quarter ended June 30, 2023 was approximately $2.1 million compared to approximately $2.7 million for t"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}